AbbVie Inc.
285.64USD
+0.4500 (+0.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABBV.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $3.78▼ | $3.85 | 0 | 8 |
| Next quarter | $3.89▼ | $4 | 2 | 5 |
| Current year | $13.96▼ | $14.15 | 0 | 10 |
| Next year | $16.2▼ | $16.33 | 3 | 6 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $3.61 | $3.65 | +0.04 (+1.2%) |
| 2026-03-31 | $2.67 | $2.65 | -0.02 (-0.8%) |
| 2025-12-31 | $2.65 | $2.71 | +0.06 (+2.2%) |
| 2025-09-30 | $1.78 | $1.86 | +0.08 (+4.2%) |
422 ratings from 44 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Goldman Sachs | Maintained | Neutral | $258 $294 | Oct 23, 2026 |
| Barclays | Maintained | Overweight | $300 $325 | Oct 21, 2026 |
| RBC Capital | Reiterated | Outperform | $280 | Oct 13, 2026 |
| UBS | Maintained | Neutral | $260 $275 | Oct 9, 2026 |
| Guggenheim | Reiterated | Buy | $288 | Oct 9, 2026 |
| JP Morgan | Maintained | Overweight | $285 $300 | Oct 8, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $285 $290 | Oct 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $296 $310 | Oct 7, 2026 |
| Scotiabank | Maintained | Sector Outperform | $280 $320 | Oct 6, 2026 |
| HSBC | Maintained | Buy | $300 $315 | Sep 10, 2026 |
| Piper Sandler | Maintained | Overweight | $298 $303 | Aug 20, 2026 |
| Wells Fargo | Maintained | Overweight | $295 $300 | Aug 17, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $300 | Aug 13, 2026 |
| BNP Paribas | Maintained | Neutral | $218 $247 | Aug 11, 2026 |
| Evercore ISI Group | Maintained | Outperform | $246 $260 | Aug 10, 2026 |
| Berenberg | Maintained | Buy | $275 | Aug 6, 2026 |
| Erste Group | Upgraded from Hold | Buy | — | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $261 $288 | Aug 4, 2026 |
| Canaccord Genuity | Maintained | Buy | $282 $290 | Aug 3, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $265 $285 | Aug 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $278 $296 | Aug 3, 2026 |
| TD Cowen | Maintained | Buy | $280 | Jul 31, 2026 |
| William Blair | Maintained | Buy | — | Jul 31, 2026 |
| Barclays | Maintained | Overweight | $275 $300 | Jul 29, 2026 |
| Canaccord Genuity | Maintained | Buy | $273 $282 | Jul 22, 2026 |
71 filings from 26 insiders · 12 buy / 1 sell over 6m
Officers and directors of ABBV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Quaggin Susan EDirector | GrantStock Equivalent Units | 59 | $261.59 | $15k | Sep 30, 2026 |
| RAPP EDWARD JDirector | GrantStock Equivalent Units | 129 | $261.59 | $34k | Sep 30, 2026 |
| DONOGHOE NICHOLASOfficer | Sell | 32.7k | $250.00 | $8.18M | Aug 14, 2026 |
| DONOGHOE NICHOLASOfficer | Exercise | 32.7k | $79.02 | $2.58M | Aug 14, 2026 |
| FREYMAN THOMAS CDirector | Grant | 1.1k | — | — | May 8, 2026 |
| FALK THOMAS JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| AUSTIN ROXANNE SCHUHDirector | Grant | 1.1k | — | — | May 8, 2026 |
| WADDELL FREDERICK HDirector | Grant | 1.1k | — | — | May 8, 2026 |
| RAPP EDWARD JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| HART BRETT JDirector | Grant | 1.1k | — | — | May 8, 2026 |
| BURNSIDE WILLIAM H LDirector | Grant | 1.1k | — | — | May 8, 2026 |
| MEYER MELODY BDirector | Grant | 1.1k | — | — | May 8, 2026 |
| ROBERTS REBECCA B.Director | Grant | 1.1k | — | — | May 8, 2026 |
| DAVIS JENNIFER LDirector | Grant | 1.1k | — | — | May 8, 2026 |
| QUAGGIN SUSAN EDirector | Grant | 1.1k | — | — | May 8, 2026 |
| PURDUE DAVID RYANOfficer | Sell | 5.2k | $233.56 | $1.22M | Mar 4, 2026 |
| SIATIS PERRY C.General Counsel | Sell | 18.7k | $233.51 | $4.38M | Mar 2, 2026 |
| SIATIS PERRY C.General Counsel | Sell | 22.4k | $230.00 | $5.15M | Feb 25, 2026 |
| SIATIS PERRY C.General Counsel | Exercise | 22.4k | $149.62 | $3.86M | Feb 25, 2026 |
| SALEKI-GERHARDT AZITAChief Operating Officer | Grant | 36.8k | — | — | Feb 18, 2026 |
No analyst notes on ABBV yet.
Analyst Ratings
27 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 8 | 16 | 5 | 0 | 1 | Buy2.00 |
| 1 mo ago | 8 | 16 | 5 | 0 | 1 | Buy2.00 |
| 2 mo ago | 8 | 17 | 5 | 0 | 1 | Buy2.00 |
| 3 mo ago | 8 | 16 | 6 | 0 | 1 | Buy2.03 |
Members whose judged calls on ABBV have played out most reliably.
No settled calls on ABBV yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice